Prostatic Cancer Versus Androgen Deficiency

• Register: ClinicalTrials.gov
• Last refreshed on: 31 January 2022
• Main ID: NCT02235142
• Date of registration: 05/09/2014
• Prospective Registration: No
• Primary sponsor: Hopital Foch
• Public title: Prostatic Cancer Versus Androgen Deficiency AndroCan
• Scientific title: Localised Cancer of Prostate and Androgen Deficiency.
• Date of first enrolment: June 3, 2013
• Target sample size: 1614
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02235142
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France, Guadeloupe, Martinique

Key inclusion & exclusion criteria

Inclusion Criteria:

- Male patients over than 18 years of age, with localized, stage I or II prostate
cancer, not receiving local treatment (radiation, phototherapy, thermotherapy,…) or
hormonal therapy, showing indication of radical prostatectomy.

Exclusion Criteria:

- Absence of radical prostatectomy indication

- Patient received local or hormonal therapy prior to surgery

- Patients already enrolled in other clinical study incompatible with the study

- Patients on a treatment which can affect hormonal level (Prednisone, Ketoconazole,
Abiraterone, Finasteride, Dutasteride)



Age minimum: 18 Years
Age maximum: N/A
Gender: Male

Health Condition(s) or Problem(s) studied

Cancer of Prostate

Intervention(s)

Other: Blood sample

Primary Outcome(s)

Testosteron Serum level [Time Frame: The day prior to surgery]

Gleason score [Time Frame: 5 years]

Secondary ID(s)

2012-A01742-41

2013/01

Source(s) of Monetary Support

Please refer to primary and secondary sponsors